Corient Private Wealth LLC Reduces Stock Position in Kenvue Inc. $KVUE

Posted by Francis Steltz on Jun 25th, 2026

Corient Private Wealth LLC cut its holdings in Kenvue Inc. (NYSE:KVUE – Free Report) by 6.2% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 471,726 shares of the company’s stock after selling 31,416 shares during the period. Corient Private Wealth LLC’s holdings in Kenvue were worth $8,151,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in KVUE. Elyxium Wealth LLC bought a new stake in Kenvue during the fourth quarter worth approximately $26,000. Physician Wealth Advisors Inc. raised its position in Kenvue by 67.5% during the fourth quarter. Physician Wealth Advisors Inc. now owns 1,533 shares of the company’s stock valued at $26,000 after purchasing an additional 618 shares during the period. MV Capital Management Inc. bought a new stake in shares of Kenvue in the 4th quarter valued at approximately $28,000. Reflection Asset Management purchased a new position in shares of Kenvue in the 4th quarter worth approximately $32,000. Finally, SBI Securities Co. Ltd. boosted its holdings in shares of Kenvue by 82.4% in the 4th quarter. SBI Securities Co. Ltd. now owns 2,273 shares of the company’s stock worth $39,000 after purchasing an additional 1,027 shares during the period. 97.64% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

KVUE has been the topic of several analyst reports. Weiss Ratings raised Kenvue from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday, June 15th. Argus upgraded Kenvue to a “hold” rating in a research report on Friday, March 6th. Citigroup dropped their price objective on shares of Kenvue from $20.00 to $19.00 and set a “neutral” rating for the company in a research note on Wednesday, April 15th. Barclays cut their price objective on shares of Kenvue from $19.00 to $18.00 and set an “equal weight” rating on the stock in a research report on Tuesday, April 14th. Finally, Zacks Research raised shares of Kenvue from a “hold” rating to a “strong-buy” rating in a research note on Friday, May 8th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and twelve have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $19.33.

Get Our Latest Analysis on KVUE

Insider Buying and Selling

In other Kenvue news, General Counsel Matthew Orlando sold 38,491 shares of the company’s stock in a transaction on Friday, May 8th. The stock was sold at an average price of $17.66, for a total value of $679,751.06. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 1.59% of the stock is owned by company insiders.

Kenvue Stock Up 2.0%

Shares of NYSE:KVUE opened at $18.77 on Thursday. Kenvue Inc. has a 1 year low of $14.02 and a 1 year high of $22.87. The business has a 50 day simple moving average of $17.60 and a two-hundred day simple moving average of $17.61. The firm has a market capitalization of $36.05 billion, a PE ratio of 22.09, a price-to-earnings-growth ratio of 1.40 and a beta of 0.54. The company has a debt-to-equity ratio of 0.67, a current ratio of 0.98 and a quick ratio of 0.70.

Kenvue (NYSE:KVUE – Get Free Report) last released its earnings results on Thursday, May 7th. The company reported $0.32 EPS for the quarter, beating analysts’ consensus estimates of $0.27 by $0.05. Kenvue had a return on equity of 20.81% and a net margin of 10.61%.The firm had revenue of $3.91 billion for the quarter, compared to analysts’ expectations of $3.84 billion. During the same quarter in the prior year, the firm posted $0.24 earnings per share. The company’s quarterly revenue was up 4.5% on a year-over-year basis. On average, equities analysts predict that Kenvue Inc. will post 1.16 EPS for the current year.

Kenvue Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, May 27th. Investors of record on Wednesday, May 13th were issued a dividend of $0.2075 per share. The ex-dividend date was Wednesday, May 13th. This represents a $0.83 dividend on an annualized basis and a yield of 4.4%. Kenvue’s payout ratio is presently 97.65%.

About Kenvue

(Free Report)

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.